SCHEMBL30209293

SCHEMBL30209293

CCOC(=O)c1cc2nc(CCl)n(CC3CCO3)c2s1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FEN1 P39748 1/20 0.37
HSD17B10 Q99714 4/20 0.37
HPGD P15428 3/20 0.37
MAPK1 P28482 2/20 0.37
HTT P42858 2/20 0.37
TSHR P16473 4/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 4/20 0.36
CASP1 P29466 2/20 0.34
CASP7 P55210 2/20 0.34
MAPT P10636 3/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 6/20 0.34
GAA P10253 4/20 0.34
TDP1 Q9NUW8 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CNR2 P34972 2/20 0.34
GLA P06280 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24575434 0.90 ALDH1A1 (0.36) HSD17B10HPGDMAPK1TSHRKDM4E
SCHEMBL24575433 0.90 ALDH1A1 (0.36) HSD17B10HPGDMAPK1TSHRKDM4E
SCHEMBL26611555 0.85 PIK3R1 (0.34) HSD17B10HPGDKDM4ECASP1CASP7
SCHEMBL26611552 0.85 PIK3R1 (0.34) HSD17B10HPGDKDM4ECASP1CASP7
SCHEMBL25789106 0.84 FEN1 (0.39) FEN1HSD17B10HPGDMAPK1HTT
SCHEMBL30209316 0.84 FEN1 (0.39) FEN1HSD17B10HPGDMAPK1HTT
SCHEMBL24401165 0.78 TSHR (0.33) FEN1HSD17B10HPGDMAPK1HTT
SCHEMBL23980939 0.76 GLP1R (0.41) FEN1HSD17B10HPGDTSHRKDM4E
SCHEMBL32669487 0.76 CASP1 (0.40) FEN1HSD17B10HPGDTSHRSMN1; SMN2
SCHEMBL22392010 0.76 CASP1 (0.40) FEN1HSD17B10HPGDTSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113831337-B GLP-1 receptor agonist, and pharmaceutical composition and use thereof 广州市恒诺康医药科技有限公司 2023-03-24 CN disclosed